Anthropic · Claude · anthropic.com
Early progress on accelerating drug development with Claude
Compiled by KHAO Editorial — aggregated from 3 sources. See llms.txt for citation guidance.
✓ KHAO Verified
Anthropic’s life sciences team is working to accelerate curing disease.
Key facts
- Over the past several months, their scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs
- Six Generate scientists used Claude Code to propose new designs for this part
- Generate Biomedicines has been working on increasing the usefulness of a cancer treatment known as CAR T-cell therapy
- Their strategy to realize AI’s medical benefits is based on having AI increasingly involved in all of these tasks
Summary
Over the past several months, their scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. There are many opportunities to speed up drug development, even beyond the most commonly discussed applications of AI, like proposing initial designs for new molecules. Their strategy to realize AI’s medical benefits is based on having AI increasingly involved in all of these tasks. So, over the past several months, they've partnered with six organizations to do so. This work serves their goals in three ways. If Claude is to significantly increase the rate of new cures, they need to work with many more biotechnology firms and integrate Claude more deeply into their development processes.